Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure.

Haematologica - 1 Mar 2009

Johnson Nathalie A, Leach Stephen, Woolcock Bruce, deLeeuw Ronald J, Bashashati Ali, Sehn Laurie H, Connors Joseph M, Chhanabhai Mukesh, Brooks-Wilson Angela, Gascoyne Randy D

Abstract excerpt

Rituximab binds an epitope on the CD20 antigen, encompassed in exon 5 of the MS4A1 gene. We sequenced this region and correlated the presence of mutations with CD20 protein expression and response to R-CHOP in patients with diffuse large B-cell lymphoma: 264 diagnostic biopsies and 15 biopsies ta...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Murine-Derived
Share to Antigens, CD20

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Binding Sites, Antibody

Share to Cyclophosphamide

Share to Doxorubicin

Share to Prednisone

Share to Rituximab

Share to Vincristine

Source

Open in PubMed Open full text

Identifiers

PMID: 19211644
DOI: 10.3324/haematol.2008.001024
PMCID: PMC2649361

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19211644-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure.PMID 19211644Read ↗

Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphomaSemantic proximity Read ↗

Genetic lesions in diffuse large B-cell lymphomas.Semantic proximity Read ↗

Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients.Semantic proximity Read ↗

De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: molecular mechanisms and correlation with rituximab sensitivity.Semantic proximity Read ↗

Identification of CD20 C-Terminal Deletion Mutations Associated with Loss of CD20 Expression in Non-Hodgkin's LymphomaSemantic proximity Read ↗

Clinicopathologic implication of A20/TNFAIP3 deletion in diffuse large B-cell lymphoma: an analysis according to immunohistochemical subgroups and rituximab treatment.Semantic proximity Read ↗

Alternative splicing of its 5′-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapiesSemantic proximity Read ↗

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.Semantic proximity Read ↗

Alternative splicing of its 5’-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapiesSemantic proximity Read ↗

High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates.Semantic proximity Read ↗

TP53 mutations and rituximab-CHOP.Semantic proximity Read ↗

A20 Mutation Is Not a Prognostic Marker for Activated B-Cell-Like Diffuse Large B-Cell Lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.